Kolmar Korea161890.KS

About Kolmar Korea

Kolmar Korea is a contract development and manufacturing company centered on cosmetics, formulating and producing skincare, makeup, and especially sun-care products for a broad roster of brand clients at home and abroad, with plants in Korea, China, and North America. It competes on formulation research, monetizing laboratory know-how through client relationships rather than consumer brands of its own. The company also holds a controlling stake in HK inno.N, a listed pharmaceutical maker it acquired from the CJ group, giving the parent a two-pillar profile of beauty manufacturing and drugs. Kolmar Korea itself sits beneath Kolmar Holdings, the family holding company.

The consolidated structure is the first thing outside investors untangle: Kolmar Korea's value combines its own ODM operations with a listed pharmaceutical subsidiary the market can price separately, inviting sum-of-the-parts analysis. The cosmetics business rides the same export wave as its ODM peers, with sunscreen regulation a distinctive sensitivity, since approval regimes for ultraviolet filters differ across countries and shape U.S. market access. Utilization at the Chinese plants tracks local demand. Above the company sits another listed holding entity, extending the chain of control and the customary Korean questions about aligned incentives.

Kolmar Korea was founded in 1990 by Yoon Dong-han, a pharmaceutical-industry veteran who secured a technology partnership with Japan's Nihon Kolmar, itself descended from the American Kolmar Laboratories lineage, bringing contract cosmetics manufacturing to Korea. The company split in 2012, creating Kolmar Holdings above the newly listed operating firm. It diversified decisively in 2018 by acquiring CJ HealthCare, the drug business renamed HK inno.N and floated separately in 2021. In 2022 Kolmar Korea purchased the global rights to the Kolmar trademark, inverting the old licensing relationship, and leadership has passed to the founder's son, Yoon Sang-hyun.

The core business sells formulation expertise: client brands commission products, Kolmar's laboratories engineer the chemistry, and its plants manufacture at per-unit prices, with sun care a specialty where its ultraviolet-filter formulations are regarded as an industry benchmark. Because development costs are recovered through production contracts, sustained client volume is what converts research into profit. The consolidated HK inno.N subsidiary adds pharmaceutical revenue from prescription medicines and consumer health drinks, a different cadence from beauty manufacturing. Kolmar's contest with Cosmax for Korean ODM leadership plays out in service speed, formulation libraries, and overseas plants serving brands in China and North America.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on Kolmar Korea →